AbbVie Inc. (NYSE:ABBV) Shares Bought by Investors Asset Management of Georgia Inc. GA ADV

Investors Asset Management of Georgia Inc. GA ADV grew its holdings in AbbVie Inc. (NYSE:ABBVFree Report) by 1.4% during the third quarter, Holdings Channel.com reports. The firm owned 18,338 shares of the company’s stock after buying an additional 260 shares during the period. AbbVie comprises about 1.5% of Investors Asset Management of Georgia Inc. GA ADV’s portfolio, making the stock its 13th biggest holding. Investors Asset Management of Georgia Inc. GA ADV’s holdings in AbbVie were worth $2,696,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ABBV. BlackRock Inc. increased its holdings in shares of AbbVie by 0.3% during the second quarter. BlackRock Inc. now owns 139,161,796 shares of the company’s stock worth $18,749,269,000 after buying an additional 440,286 shares in the last quarter. State Street Corp grew its position in shares of AbbVie by 1.5% in the 2nd quarter. State Street Corp now owns 78,182,567 shares of the company’s stock valued at $10,533,537,000 after purchasing an additional 1,156,130 shares during the period. Capital International Investors raised its holdings in shares of AbbVie by 0.9% during the second quarter. Capital International Investors now owns 43,152,741 shares of the company’s stock worth $5,813,873,000 after acquiring an additional 404,379 shares during the period. Geode Capital Management LLC raised its stake in shares of AbbVie by 2.7% in the 2nd quarter. Geode Capital Management LLC now owns 34,952,938 shares of the company’s stock valued at $4,697,046,000 after purchasing an additional 907,917 shares during the period. Finally, Morgan Stanley lifted its holdings in shares of AbbVie by 17.9% in the fourth quarter. Morgan Stanley now owns 31,571,750 shares of the company’s stock valued at $5,102,311,000 after purchasing an additional 4,785,277 shares in the last quarter. Institutional investors and hedge funds own 67.86% of the company’s stock.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 2,912 shares of AbbVie stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $154.72, for a total transaction of $450,544.64. Following the completion of the transaction, the executive vice president now owns 55,903 shares of the company’s stock, valued at $8,649,312.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.26% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Raymond James raised their target price on shares of AbbVie from $181.00 to $189.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. William Blair upgraded AbbVie from a “market perform” rating to an “outperform” rating in a report on Monday, January 29th. UBS Group decreased their price target on AbbVie from $157.00 to $150.00 and set a “neutral” rating for the company in a research note on Friday, October 20th. Deutsche Bank Aktiengesellschaft began coverage on AbbVie in a report on Thursday, November 9th. They issued a “hold” rating and a $150.00 price objective for the company. Finally, Truist Financial upped their price target on shares of AbbVie from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 6th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $175.36.

View Our Latest Stock Report on ABBV

AbbVie Price Performance

Shares of ABBV stock traded down $1.01 during trading on Monday, hitting $173.07. The company had a trading volume of 3,462,925 shares, compared to its average volume of 5,406,210. The stock’s 50-day moving average price is $159.86 and its 200 day moving average price is $151.31. The firm has a market capitalization of $311.53 billion, a P/E ratio of 63.50, a price-to-earnings-growth ratio of 2.21 and a beta of 0.57. The company has a debt-to-equity ratio of 4.59, a quick ratio of 0.84 and a current ratio of 0.96. AbbVie Inc. has a one year low of $130.96 and a one year high of $175.91.

AbbVie (NYSE:ABBVGet Free Report) last released its earnings results on Friday, February 2nd. The company reported $2.79 earnings per share for the quarter, topping the consensus estimate of $2.76 by $0.03. AbbVie had a return on equity of 154.73% and a net margin of 8.95%. The firm had revenue of $14.30 billion during the quarter, compared to analysts’ expectations of $14.02 billion. During the same period in the prior year, the company earned $3.60 earnings per share. The company’s quarterly revenue was down 5.4% on a year-over-year basis. Equities analysts expect that AbbVie Inc. will post 11.14 EPS for the current fiscal year.

About AbbVie

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Featured Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.